Inbjudan till presskonferens: SEB presenterar Eastern European Outlook
October 06, 2006 05:00 ET
|
SEB
På onsdag den 11 oktober presenterar SEB Eastern European Outlook. Några centrala ämnen som tas upp är:
Hotar politisk turbulens den goda ekonomiska utvecklingen i Centraleuropa?
Tar...
Marginally lower borrowing requirement than expected in September
October 06, 2006 03:30 ET
|
Riksgälden
The Swedish central government borrowing requirement in September was SEK 2.7 billion. This is SEK 0.9 billion lower than our latest forecast.
The primary borrowing requirement (all central...
Något lägre lånebehov än väntat i september
October 06, 2006 03:30 ET
|
Riksgälden
Statens lånebehov i september var 2,7 miljarder kronor. Det är 0,9 miljarder kronor lägre än i vår senaste prognos.
Det primära lånebehovet (alla statliga betalningar exklusive...
Letter of Intent for FPSO contract
October 06, 2006 03:09 ET
|
Prosafe SE
Should the LOI result in a contract, this would have a firm period of seven years plus options to extend the contract to up to 15 years. The estimated contract value of the firm period is USD 332...
Letter of Intent for FPSO contract
October 06, 2006 03:00 ET
|
Prosafe SE
extend the contract to up to 15 years. The estimated contract value of the firm period is USD 332 million.
The award is a result of Prosafe's strong track record, engineering competence and...
Van Lanschot analyst meeting - 6 October 2006
October 06, 2006 03:00 ET
|
Van Lanschot Kempen NV
Van Lanschot is today - 6 October 2006 - holding a meeting for analysts in 's-Hertogenbosch. During the meeting, presentations will be given on the following topics:
Private Banking
Private...
Van Lanschot analistenbijeenkomst - 6 oktober 2006
October 06, 2006 03:00 ET
|
Van Lanschot Kempen NV
Vandaag - 6 oktober 2006 - houdt Van Lanschot in 's-Hertogenbosch een analistendag.Hierbij zullen presentaties worden gegeven inzake:
Private Banking
Private Investments
Private...
Portfolio update
October 06, 2006 02:01 ET
|
Novo Nordisk A/S
At its Capital Markets Day today, Novo Nordisk will report on solid progress in its pipeline of clinical development projects within diabetes care and biopharmaceuticals and confirm the positive...
NIH Completes Collaborative Phase II Study with Santhera's compound SNT-MC17/idebenone in Friedreich's Ataxia (FRDA)
October 06, 2006 02:00 ET
|
Santhera Pharmaceuticals Holding AG
Bethesda, Maryland, USA, and Liestal, Switzerland - The US National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) and Santhera Pharmaceuticals, a...
NIH schliesst Phase-II-Studie mit Santhera's SNT-MC17/idebenone bei Friedreich-Ataxie (FRDA) ab
October 06, 2006 02:00 ET
|
Santhera Pharmaceuticals Holding AG
Bethesda, Maryland/USA und Liestal, Schweiz, 6. Oktober 2006 - Das US National Institute of Neurological Disorders and Stroke (NINDS) der National Institutes of Health (NIH) und Santhera...
- January 11, 2025 00:17 ET LFG Inc. Partners with GlobiancePay to Launch the LFG Debit Card with Staking Rewards
- January 10, 2025 21:59 ET Yang Rongfeng Pioneers Modular Construction in Australia